
Biocytogen Licenses RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform to Taisho Pharmaceutical
Biocytogen Enters Platform Licensing Agreement with Taisho to Expand Use of RenNano® Antibody Discovery Technology Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company recognized for its innovation in antibody-based drug discovery, has announced a new strategic collaboration with Taisho…












